Viking Global Investors

Founded 1999

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 86
Average round size
info
The average size of a deal this fund participated in
$106M
Portfolio companies 78
Rounds per year 3.91
Lead investments 23
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Exits 19
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Biopharma
  • Medical
  • Pharmaceutical
Summary

Viking Global Investors appeared to be the Corporate Investor, which was created in 1999. The main department of described Corporate Investor is located in the Greenwich. The venture was found in North America in United States.

The top amount of exits for fund were in 2019. Comparing to the other companies, this Viking Global Investors performs on 11 percentage points less the average number of lead investments. The fund is constantly included in 2-6 deals per year. When the investment is from Viking Global Investors the average startup value is more than 1 billion dollars. Deals in the range of more than 100 millions dollars are the general things for fund. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2019.

The overall number of key employees were 1.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Roivant Sciences, Credit Karma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Agriculture, Genetics.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Viking Global Investors, startups are often financed by Illumina Accelerator, Felicis Ventures, Tenaya Capital. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Wellington Management, T. Rowe Price. In the next rounds fund is usually obtained by Y Combinator, Senator Investment Group, SVG Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Viking Global Investors:
Typical Co-investors
Viking Global Investors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Viking Global Investors:

Funds with similar focus

Funds from United States, Greenwich
Funds with similar focus located in United States, Greenwich:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
The Garage Soho United Kingdom, London
ZenShin Capital United States, Menlo Park
The Trelys Funds United States, Cary
Adamant Biomedical Investments AG Switzerland, Zürich
Generali Investments Europe Italy, Milan
Omron Corporation Japan, Kyoto
Ford Allen United States, Miami Beach
T.C.L. Industries Holdings China, New Territories
Saha Fund India, Bengaluru
Green Frog Innovations United States, Norwood
Banco BPM Italy, Milan
Innovate Financial Health Canada, Toronto
Yushi Asset Management China, Shanghai
BNH -
Jingang Zichan China, Suzhou
Chelsey Capital United States, New York
Numu Capital -
Haitong-Fortis Private Equity Fund Management China, Shanghai
Curzon Investment -
Sunflower Development Group -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Biome Makers

Agriculture
Bioinformatics
Biotechnology
Genetics
Wine And Spirits
1
$15M25 Aug 2021 United States, San Francisco

Apeel Sciences

Advanced Materials
Agriculture
AgTech
Biotechnology
Food Processing
Waste Management
1
$250M18 Aug 2021 United States, " United States"}

Talkdesk

Call Center
Cloud Computing
CRM
Customer Service
SaaS
Software
1
$230M12 Aug 2021 United States, San Francisco

Pepgen

Biotechnology
Clinical Trials
Medical
n/a
$112M05 Aug 2021 United Kingdom, Oxford

Zentera Therapeutics

Biotechnology
Pharmaceutical
1
$75M04 Aug 2021 China, Shanghai

Genomatica

Chemical Engineering
CleanTech
Manufacturing
Renewable Energy
1
$118M27 Jul 2021 United States, San Diego

Sema4

Artificial Intelligence
Health Care
Health Diagnostics
Machine Learning
Medical
Predictive Analytics
n/a
$350M23 Jul 2021 United States, Stamford

Arctic Wolf

Cyber Security
Information Technology
Network Security
Software
1
$150M13 Jul 2021 United States, " United States"}

Antheia

Biotechnology
Health Care
Manufacturing
1
$73M30 Jun 2021 United States, Menlo Park
News
Automation-driven sales engagement platform Groove nabs $45M

– Groove, an automation-driven sales engagement platform, announced that it closed a $45 million series B round led by Viking Global Investors with participation from Capital One Ventures, Level Equity, Quest Venture Partners, and Uncork Capital.
– The funds bring the company’s total raised to over $57 million to date, which cofounder and CEO Chris Rothstein says will be put toward product development and international workforce growth.
– It’s Groove’s assertion that the pandemic-fueled shift to digital selling is driving the convergence of sales engagement and revenue operations.
– But digital selling has also exposed a weakness in some companies’ customer relationship management (CRM) software: a lack of adoption.

Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Viking Global Investors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: